HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Can common hepatic artery lymph node dissection be safely omitted in surgery for clinical T1N0 thoracic esophageal squamous cell carcinoma?

Abstract
Common hepatic artery lymph node dissection is regarded as a standard procedure in esophageal cancer surgery because of aggressive lymphatic dissemination of esophageal cancer. However, lymph node dissection can prolong operation time and may be associated with complications such as chylous ascites. Here, we aimed to evaluate the effectiveness of common hepatic artery lymph node dissection in clinical T1N0 thoracic esophageal squamous cell carcinoma. Between 1996 and 2009, 1390 patients underwent surgery for esophageal cancer in our institution, and 209 were found to have clinical T1N0 disease. Exclusion criteria were nonsquamous carcinoma, double primary cancer, definite distant metastasis, administration of neoadjuvant treatment, and incomplete abdominal lymph node dissection. We retrospectively analyzed medical records, operative and pathologic data, and follow-up information. Forty-two patients were excluded from the study. Among the 167 enrolled patients, preoperative endoscopic ultrasound evaluation was performed in 160 patients. Fifty-two patients had distal esophageal or esophagogastric junction tumor. Surgery included 2 cases of tri-incisional esophagectomy, 17 cases of transhiatal esophagectomy, and 148 cases of two-field esophagectomy (Ivor Lewis operation). Common hepatic artery lymph node dissection was performed in all cases, and none of the patients had metastasis. Mean follow-up period was 35.4 ± 28.7 months. In-hospital mortality was one, and 5-year survival rate was 80.6%. Among the 15 patients with recurrence, there were two distant metastases and five distant and local recurrences but no intra-abdominal recurrence with common hepatic artery lymph node. Common hepatic artery lymph node dissection may be safely omitted in surgery for clinical T1N0 esophageal squamous cell carcinoma when preoperative evaluations including chest computed tomography, positron emission tomography and computed tomography, and esophagogastroduodenoscopy or endoscopic ultrasound are performed.
AuthorsY M Shim, J S Park, M Lee, Dohun Kim, K Kim
JournalDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus (Dis Esophagus) Vol. 26 Issue 3 Pg. 272-5 (Apr 2013) ISSN: 1442-2050 [Electronic] United States
PMID22642487 (Publication Type: Journal Article)
Copyright© 2012 Copyright the Authors. Journal compilation © 2012, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.
Topics
  • Carcinoma, Squamous Cell (pathology, secondary, surgery)
  • Endoscopy, Digestive System (methods)
  • Endosonography (methods)
  • Esophageal Neoplasms (pathology, surgery)
  • Esophagectomy (methods)
  • Female
  • Follow-Up Studies
  • Hepatic Artery (pathology)
  • Humans
  • Lymph Node Excision (methods)
  • Lymph Nodes (pathology)
  • Lymphatic Metastasis (pathology)
  • Male
  • Middle Aged
  • Multimodal Imaging (methods)
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local (pathology)
  • Neoplasm Staging
  • Positron-Emission Tomography
  • Postoperative Complications
  • Radiography, Thoracic (methods)
  • Retrospective Studies
  • Survival Rate
  • Tomography, X-Ray Computed (methods)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: